Delaere Ian, Harris Kerry, Gaskin Sharyn, Tefera Yonatal, Mitchell Krystle, Springer David, Mills Simon
Expotox Pty Ltd, Adelaide, South Australia 5000, Australia; Department of Health and Wellbeing, Adelaide, South Australia 5000, Australia.
Integrative Health Solutions, Belair. South Australia 5052, Australia.
Environ Int. 2025 Aug;202:109609. doi: 10.1016/j.envint.2025.109609. Epub 2025 Jun 16.
In 2018/2019 a voluntary baseline biomonitoring survey (n = 916) identified firefighters at a fire station with substantially elevated serum perfluorooctane sulfonic acid (PFOS) and perfluorohexane sulfonic acid (PFHxS) concentrations. The South Australian Metropolitan Fire Service (SAMFS) initiated a voluntary treatment program (VTP) to address the impact of these exposures (participants n = 19). At the conclusion of the VTP, a retrospective analysis of a de-identified and coded serum PFOS and PFHxS concentration spreadsheet was conducted independently of the VTP.
This study reports longitudinal changes in serum PFOS and PFHxS concentrations and compares participants accessing the VTP with an observational group that did not seek treatment.
The dataset included a treatment group (n = 19) and an observation group (n = 9). The treatment group was further subdivided into three subgroups: (1) plasma donation (n = 2), (2) cholestyramine administration (n = 12), and (3) a combination of plasma donation and cholestyramine administration (n = 5). Repeat samples identified participants' maximum and minimum serum PFOS and PFHxS concentrations. The calculations only included data from participants whose serum PFOS and PFHxS concentrations decreased. Apparent half-lives were estimated using one-compartment first-order elimination kinetics. The study did not conduct statistical comparisons; conclusions were drawn based on visual observations.
The average change in serum concentration for the treatment group (PFOS: maximum decrease of 162 ng/mL, annual decrease of 41 %, with a half-life of 1.2 years; PFHxS: maximum decrease of 37 ng/mL, annual decrease of 32 %, with a half-life of 2.5 years) was compared with the observation group (PFOS: maximum decrease of 41 ng/mL, annual decrease of 12 %, with a half-life of 7.3 years; PFHxS: maximum decrease of 6 ng/mL, annual decrease of 10 %, with a half-life of 9.4 years).
This study shows that participants who received treatment eliminated PFOS and PFHxS from their serum at a greater rate than the observation group.
在2018/2019年，一项自愿性基线生物监测调查（n = 916）发现，某消防站的消防员血清全氟辛烷磺酸（PFOS）和全氟己烷磺酸（PFHxS）浓度大幅升高。南澳大利亚都市消防队（SAMFS）启动了一项自愿治疗计划（VTP），以应对这些暴露的影响（参与者n = 19）。在VTP结束时，对一份经过去识别和编码的血清PFOS和PFHxS浓度电子表格进行了回顾性分析，该分析独立于VTP进行。
本研究报告血清PFOS和PFHxS浓度的纵向变化，并将接受VTP治疗的参与者与未寻求治疗的观察组进行比较。
数据集包括一个治疗组（n = 19）和一个观察组（n = 9）。治疗组进一步细分为三个亚组：（1）血浆捐献（n = 2），（2）服用消胆胺（n = 12），以及（3）血浆捐献与服用消胆胺联合（n = 5）。重复采样确定了参与者血清PFOS和PFHxS的最高和最低浓度。计算仅包括血清PFOS和PFHxS浓度下降的参与者的数据。使用单室一级消除动力学估计表观半衰期。该研究未进行统计比较；结论基于直观观察得出。
治疗组血清浓度的平均变化（PFOS：最大下降162 ng/mL，年下降41%，半衰期为1.2年；PFHxS：最大下降37 ng/mL，年下降32%，半衰期为2.5年）与观察组（PFOS：最大下降41 ng/mL，年下降12%，半衰期为7.3年；PFHxS：最大下降6 ng/mL，年下降10%，半衰期为9.4年）进行了比较。
本研究表明，接受治疗的参与者血清中PFOS和PFHxS的消除速度比观察组更快。
